Just a few neoantigens may be enough for T cells to control
4.8 (286) · $ 15.50 · In stock
In a phase II clinical trial, 29 patients with metastatic castration-resistant prostate cancer were treated with ipilimumab after tumor resection. Median radiographic PFS was 3 months, median clinical PFS was 2 months, and median OS was 24 months. Best ORR was stable disease in 37% of patients. In the “favorable” cohort (PFS>6 months, median OS of 45 months), pretreatment tumors had increased CD8+ T cell density and IFNγ response gene signature compared with the “unfavorable” cohort (PFS<6 months, median OS of 5 months), while TMB was similar between cohorts. In post-treatment PBMCs, CD8+ T cell responses to PSMA, PAP, and/or neoantigens were found in 4 patients, all of which were in the favorable cohort.
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges, Biomarker Research
A) Strategies of identifying neoantigen-specific T cells. The
Neoantigens and their potential applications in tumor immunotherapy (Review)
All Antigens Are Not Created Equal
Weekly Digests for April 2020
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells, Molecular Cancer
CD4+ CAR T cells kill tumor cells from a distance with IFNγ
When neoantigen expression is low, the T cells won't go
Targeting Cancer Neoantigens and Metabolic Change in T-cells Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Neoantigens: promising targets for cancer therapy
Frontiers The good and the bad of T cell cross-reactivity: challenges and opportunities for novel therapeutics in autoimmunity and cancer
